news
& press
Discover the latest news & press releases of our company regarding our employees, our business and our environment.
Microinnova Featured in Chemistry Today
In the latest issue of Chemistry Today, Microinnova’s Dr. Dirk Kirschneck joined a panel of industry experts to discuss the future of agile manufacturing and supply chain resilience.
Maximizing Efficiency: 5 Ways Flow Chemistry Slashes OPEX
Ready to reduce OPEX and push Operational Excellence?
Continuous flow chemistry transforms rigid batch processes into agile, high-speed operations. Discover the 5 key factors driving this shift at Microinnova, from automated control to resource minimization.
7 Factors of Hidden ROIs: Why Continuous Flow Pays for Itself (Beyond the Sticker Price)
Calculate your continuous flow ROI by looking beyond initial CAPEX. Learn how yield efficiency, autonomous manufacturing, and reduced footprints drive cost leadership in the European chemical industry.
5 Common Challenges in Process Scale-Up & How to Overcome Them
Moving from the lab to commercial production is rarely a linear journey. At Microinnova, we see the same five hurdles trip up projects again and again. We are thinking superior processing for tomorrow.
Bridging Graz and Silicon Valley: Designing the Future of AI Leadership ✈️
From Stanford to the Lab: Microinnova is scaling AI 🚀
Our founder, Dr. Dirk Kirschneck, is currently embedded in Silicon Valley, learning from the best at Stanford University and Open Austria.
We aren’t just watching the AI revolution. We’re driving it. At Microinnova, AI is already an “active engine” in our engineering.
Modular Flow Chemistry and MTP: Transforming Pharmaceutical Manufacturing for Agility, Safety, and Speed
The pharma industry is embracing modular flow chemistry to overcome the limits of batch production. With MTP (Module Type Package) plants, companies gain unmatched flexibility, safety, and speed — enabling agile scale-up from R&D to production, cutting time-to-market, reducing engineering complexity, and handling even hazardous reactions more safely.
Engineering the Future Together: Inside Microinnova and Hovione’s Modular Manufacturing Vision
The latest Off Script podcast episode with Andy Lundin (Senior Editor at Pharma Manufacturing) dives into how flow chemistry, process intensification, and modular automation are accelerating the journey from development to commercial scale.
Modular Plants: Protecting Investment in Uncertain Times
How do you future-proof process plant investments in an uncertain world? One answer: build in the freedom to adapt.
Santa’s Dirty Wishlist – For Chemists Who Love Danger (But Prefer Not to Die)
This Christmas, Santa isn’t bringing toys. He’s bringing the reagents every chemist secretly wants but never dares to touch. Diazomethane, fluorine, HF, phosgene, nitrogen triiodide… the stuff of legends, the stuff of nightmares.
Modular API Manufacturing: The “Plug-and-Produce” Approach for Speed & Flexibility
Modular API manufacturing is redefining speed and flexibility in pharmaceutical development. Instead of building new chemical synthesis plants from scratch, plug-and-produce modules, such as Microinnova’s FlowKiloLab® and FlowTonPlant, allow companies to assemble manufacturing systems quickly using pre-engineered components.
🔬 Shaping the Future of Pharmaceutical Manufacturing: PHARMECO Consortium Meeting 💡
From participating in the #PHARMECO consortium meeting in Graz to welcoming the PHARMECO team at our Microinnova site, we had the chance to connect, share progress, and dive deeper into the technologies driving the project. It was a pleasure to be visited by AbbVie, AstraZeneca, Boehringer Ingelheim, CPI, Universiteit Gent, Merck Gruppe, Pfizer, RCPE – Research Center Pharmaceutical Engineering GmbH, RISE Research Institutes of Sweden, Sanofi, Servier, UCB and Universität Graz.
Continuous Manufacturing for the Simmons-Smith Reaction: A Step Forward in Flow Chemistry
🚀 Excited to share our new publication in Organic Process Research & Development!
Cyclopropane rings are highly valuable in pharmaceuticals, but one of the main ways to make them, the Simmons–Smith reaction, has long been limited by safety concerns, handling of unstable intermediates, and labor-intensive purification steps.